Curtis Lab Medicine

The research program of Associate Professor Curtis aims to identify improved therapies for acute leukemia and related blood cancers through the use of mouse models to dissect the genetic and epigenetic mechanisms that control the fate of normal and malignant hematopoietic stem cells. In addition, A/Prof Curtis uses ENU-mutagenesis for discovery of genes that regulate hematopoiesis. Specific areas of focus include the bHLH transcription factor complex that drives T-cell acute lymphoblastic leukemia, the mechanisms of oncogene-induced apoptosis in myelodysplasia, the role of epigenetic changes in acute myeloid leukemia and myelodysplasia and the therapeutic potential of small molecule inhibitors of the protein arginine methyltransferase, PRMT5

This allocation will also be used as an archive of the general work done as part of the Victorian Bioinformatics Consortium.